SCHEMBL420820

SCHEMBL420820

Nc1noc2cccc(Br)c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.54
KIT P10721 12/20 0.54
FLT3 P36888 9/20 0.54
AURKB Q96GD4 7/20 0.49
MAP4K4 O95819 2/20 0.49
PDGFRB P09619 2/20 0.49
PIM1 P11309 2/20 0.49
FGFR1 P11362 2/20 0.49
PDGFRA P16234 2/20 0.49
PRKACA P17612 2/20 0.49
LTK P29376 2/20 0.49
GRK5 P34947 2/20 0.49
CDK8 P49336 2/20 0.49
CDK7 P50613 2/20 0.49
CDK9 P50750 2/20 0.49
LIMK1 P53667 2/20 0.49
MAP2K1 Q02750 2/20 0.49
ACVR1 Q04771 2/20 0.49
MST1R Q04912 2/20 0.49
MAP4K2 Q12851 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2445430 0.79 KDR (0.58) KDRKITFLT3AURKBMAP4K4
Hydrochloric Acid SCHEMBL5103456 0.78 KDR (0.56) KDRKITFLT3AURKBMAP4K4
SCHEMBL2882058 0.76 KDR (0.57) KDRKITFLT3AURKBMAP4K4
SCHEMBL21807299 0.76 KDR (0.38) KDRKITFLT3AURKBMAP4K4
SCHEMBL1781743 0.76 KDR (0.54) KDRKITFLT3AURKBMAP4K4
SCHEMBL31605557 0.76 KDR (0.54) KDRKITFLT3AURKBMAP4K4
SCHEMBL8249434 0.76 KDR (0.54) KDRKITFLT3AURKBMAP4K4
SCHEMBL30784448 0.76 KDR (0.38) KDRKITFLT3AURKBMAP4K4
SCHEMBL16646799 0.76 KDR (0.57) KDRKITFLT3AURKBMAP4K4
Hydrochloric Acid SCHEMBL5050322 0.74 KDR (0.53) KDRKITFLT3AURKBMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122071471-A Heterocyclic compounds 武田药品工业株式会社 2026-05-22 CN disclosed
CN-122010946-A Heterocyclic compounds 武田药品工业株式会社 2026-05-12 CN disclosed
CN-122010945-A Heterocyclic compounds 武田药品工业株式会社 2026-05-12 CN disclosed
US-20260062393-A1 Compounds CTXT PTY LTD (AU) 2026-03-05 US disclosed
US-12534471-B2 Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-01-27 US disclosed
WO-2025229494-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-11-06 WO disclosed
EP-4612145-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2025-09-10 EP disclosed
US-12365655-B2 Compounds CTXT PTY LTD (AU) 2025-07-22 US disclosed
CN-112334466-B Compounds of formula (I) CTXT私人有限公司 2025-05-30 CN disclosed
CN-119638639-A Biaryl compound with anti-cell necrotic apoptosis activity, derivative and application thereof 中国药科大学 2025-03-18 CN disclosed
EP-1638941-B1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LAB (US) 2010-06-02 EP disclosed
US-20090286784-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-11-19 US disclosed
US-7598283-B2 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors ABBOTT LABORATORIES, INC. (US) 2009-10-06 US disclosed
US-20080076767-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBVIE INC. 2008-03-27 US disclosed
US-7297709-B2 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors ABBOTT LABORATORIES (US) 2007-11-20 US disclosed
CN-1826324-A Indazole, benzisoxazole and benzisothiazole kinase inhibitors ABBOTT LAB (US) 2006-08-30 CN disclosed
EP-1638941-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-03-29 EP disclosed
US-20050020603-A1 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors ABBVIE INC. 2005-01-27 US disclosed
WO-2004113304-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-12-29 WO disclosed
US-20040235892-A1 Indazole and benzisoxazole kinase inhibitors ABBOTT LABORATORIES 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076767-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABL1, BLK, BTK KDR 724/4885KIT 361/4885FLT3 41/4885
US-20050020603-A1 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors ABL1, BLK, BTK KDR 724/4885KIT 361/4885FLT3 41/4885
US-20260062393-A1 Compounds SCN2B, ABCB11, SCN1B KDR 1022/4885KIT 2385/4885FLT3 2336/4885
US-20040235892-A1 Indazole and benzisoxazole kinase inhibitors ABL1, MAP3K19, MAP3K1 KDR 800/4885KIT 238/4885FLT3 41/4885
US-20090286784-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABL1, BLK, BTK KDR 724/4885KIT 361/4885FLT3 41/4885
US-12365655-B2 Compounds SLC10A1, ABCB11, PCSK9 KDR 4505/4885KIT 519/4885FLT3 2101/4885
US-12534471-B2 Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof HCRTR2, HCRTR1, NPY1R KDR 2969/4885KIT 4421/4885FLT3 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.